# BridgeBio Pharma, Inc. (BBIO) FY2026 Q3 Revenue by Geography

- Company: BridgeBio Pharma, Inc. (BBIO)
- Statement: BridgeBio Pharma, Inc. (BBIO) FY2026 Q3 P&L / Income Statement, https://plicit.ai/financials/bbio/fy2026-q3-income-statement
- Period: 2026-07-01 to 2026-09-30
- Filing: Q3 FY2026 10-Q, filed 2026-10-29, accession number 0001743881-26-000034
- Page: https://plicit.ai/financials/bbio/fy2026-q3-income-statement/revenue-by-geography
- Chart image: https://plicit.ai/charts/bbio-fy2026-q3-revenue-by-geography-sankey.png

## Chart details: Revenue by Geography

Income statement for 2026-07-01 through 2026-09-30. View: Geography. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Total revenues, net**: 353,171,000 US dollars
- **Total cost of revenues**: 20,450,000 US dollars
- **Gross profit (calculated)**: 332,721,000 US dollars
- **Operating expenses (calculated)**: 344,360,000 US dollars
- **Loss from operations**: negative 11,639,000 US dollars
- **Total other expense, net**: negative 47,628,000 US dollars
- **Loss before income taxes**: negative 59,267,000 US dollars
- **Provision for (benefit from) income taxes**: 1,229,000 US dollars
- **Net loss**: negative 60,496,000 US dollars
- **UNITED STATES (calculated)**: 253,223,607 US dollars
- **Asia Pacific (calculated)**: 2,472,197 US dollars
- **EMEA (calculated)**: 97,475,196 US dollars
- **Restructuring, impairment, and related charges**: 0 US dollars
- **Research and development**: 143,506,000 US dollars
- **Selling, general and administrative**: 200,854,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
- Of which attributable to BridgeBio Pharma, Inc.: −$56.71 M; to noncontrolling interests: −$3.79 M.

## Key Takeaways

- The United States still brought in 72% of sales, against 90% a year earlier.
- EMEA's share rose from 7.7% to 27.6%, and its dollars rose from $9.29 M to $97.48 M.
- APAC fell 24% from a year earlier, while total revenue rose 193% as the company grew.
- Its sales outside the home country reached 28%, up from 10% a year earlier.

## The Unvarnished Truth

### BridgeBio's US sales share fell from 90% to 72% in a year

Sales are concentrated in the United States: 72% of this quarter's $353.17 M, down from 90% a year earlier. The filing gives regions only as percentages, so the dollar figures on this page are estimates, each share times total sales. Only the percentages are reported; the dollars are our arithmetic on them. That matters because the EMEA slice rose from $9.29 M to $97.48 M, the fastest riser on the page. The filing does not give the regional dollar amounts.

Why did Europe, the Middle East and Africa jump? Its share went from 7.7% to 27.6% of sales, and the filing says revenue is attributed to regions by where customers or license partners are located. The quarter's $75.0 M sales milestone sits in the license line, which the filing ties to a Bayer agreement. If that milestone is attributed to a partner in the EMEA region, it would account for most of the $88.18 M rise there. The filing does not say where it was booked.

What it means: the regional story is thinner than the headline suggests. APAC slipped from $3.26 M to $2.47 M, down 24%, while the United States lost share. What would settle it is a regional table that shows where the milestone was booked and whether the percentages match the dollars. Until then, the regional dollars stay an estimate built on rounded shares, and the milestone's place in that picture stays unproven. Will the next filing break out the milestone by region?

## Intelligent Insights for Investors

### How much of BridgeBio's sales come from outside its home country?

Most of its sales are in the United States, but 28% came from abroad this quarter, against 10% a year earlier.

### Which part of BridgeBio's sales by region lost the most ground over the past year?

APAC: its revenue fell 24% from a year earlier, while revenue as a whole rose 193%.

## Intelligent Insights for Suppliers

### How much does BridgeBio depend on the biggest piece of its sales by region?

Heavily: the United States brought in 72% of these sales this quarter, against 28% for EMEA, the next largest.
